latest, page-7

Normally I would give a "small" credit to the director who makes an attempt to raise capital and then "tries" to put it into some use demonstrating to the investors they are "pursuing" exploration but these directors just sat there in that office and leech off their salary. Then they have the callus thicken face to backflip and go back to the shell company they came from, a failed biotech.

I suggest the bigger SI holders pay Slater Gordon a visit to give director incentive or clear the office! What happen to Macquarie who was ramming this down their client or perhaps just collateral damage since they are plenty of rosy investors to pluck form the new generations of low hanging fruit?